This article was originally published in The Gray Sheet
Executive SummaryAppoints Arthur Collins chief operating officer with responsibility for operations "both inside and outside the United States." Collins, previously exec VP and president of Medtronic International, came to Medtronic in June 1992 from Abbott Laboratories, where he headed its diagnostic business units. Collins fills the position that was left vacant by William George, who became president and chief executive officer of the company in May 1991
You may also be interested in...
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.